Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.55 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 7/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.47 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498791 | 1.00 | CYSLTR1 (0.59) | CYSLTR1ABCG2CYSLTR2MAOBAPP | |
| SCHEMBL498936 | 0.86 | MAPT (0.50) | APP | |
| SCHEMBL30383422 | 0.86 | MAPT (0.50) | APP | |
| SCHEMBL499270 | 0.82 | TTR (0.48) | APP | |
| SCHEMBL498877 | 0.80 | MAPT (0.47) | CYSLTR1ABCG2MAOBAPPMAOA | |
| SCHEMBL498928 | 0.77 | CYP1A1 (0.51) | ABCG2MAOBDHODHMAOACYP1B1 | |
| SCHEMBL27747073 | 0.76 | ALDH1A1 (0.56) | — | |
| SCHEMBL13480847 | 0.76 | MAOB (0.72) | ABCG2MAOBMAOACYP1B1CXCL12 | |
| SCHEMBL25265340 | 0.74 | CYSLTR1 (1.00) | CYSLTR1ABCG2CYSLTR2MAOBAPP | |
| SCHEMBL25197758 | 0.74 | SRD5A2 (0.59) | ABCG2MAOBAPPDHODHMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |